JP2025512515A5 - - Google Patents

Info

Publication number
JP2025512515A5
JP2025512515A5 JP2024560788A JP2024560788A JP2025512515A5 JP 2025512515 A5 JP2025512515 A5 JP 2025512515A5 JP 2024560788 A JP2024560788 A JP 2024560788A JP 2024560788 A JP2024560788 A JP 2024560788A JP 2025512515 A5 JP2025512515 A5 JP 2025512515A5
Authority
JP
Japan
Prior art keywords
chimeric protein
mucosal
peptide fragment
variants
adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065734 external-priority patent/WO2023201306A1/en
Publication of JP2025512515A publication Critical patent/JP2025512515A/ja
Publication of JP2025512515A5 publication Critical patent/JP2025512515A5/ja
Pending legal-status Critical Current

Links

JP2024560788A 2022-04-14 2023-04-13 インフルエンザ感染症を予防又は治療するための組成物 Pending JP2025512515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263331100P 2022-04-14 2022-04-14
US63/331,100 2022-04-14
PCT/US2023/065734 WO2023201306A1 (en) 2022-04-14 2023-04-13 Compositions for preventing or treating influenza infections

Publications (2)

Publication Number Publication Date
JP2025512515A JP2025512515A (ja) 2025-04-17
JP2025512515A5 true JP2025512515A5 (cg-RX-API-DMAC7.html) 2026-04-21

Family

ID=88330391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560788A Pending JP2025512515A (ja) 2022-04-14 2023-04-13 インフルエンザ感染症を予防又は治療するための組成物

Country Status (5)

Country Link
US (2) US12459988B2 (cg-RX-API-DMAC7.html)
EP (1) EP4508077A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512515A (cg-RX-API-DMAC7.html)
CA (1) CA3256034A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023201306A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111178332A (zh) * 2012-05-18 2020-05-19 苹果公司 用于操纵用户界面的设备、方法和图形用户界面
WO2025142818A1 (ja) * 2023-12-27 2025-07-03 遠友ファーマ株式会社 融合タンパク質、複合体およびその応用
EP4684804A1 (en) 2024-07-26 2026-01-28 Freie Universität Berlin Conjugation product comprising an antigen binding moiety and a mucin binding moiety

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
AU2007281433A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
CN105490420B (zh) 2010-06-25 2018-01-12 菲舍尔和佩克尔应用有限公司 马达转子、马达、包含该转子的电器和该转子的制造方法
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
EP2731967B1 (en) * 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
WO2013081463A2 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン,エルエルシー A型インフルエンザを治療する方法
JP7332157B2 (ja) 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体
US20200095327A1 (en) 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
EP3758749A4 (en) 2018-03-02 2022-07-06 The University of Chicago METHOD AND COMPOSITION FOR NEUTRALIZING INFLUENZA
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
WO2020041540A1 (en) 2018-08-23 2020-02-27 Vanderbilt University Human monoclonal antibodies to a new universal influenza a hemagglutinin head domain epitope
CN111423507B (zh) 2019-01-10 2022-04-15 中国科学院分子细胞科学卓越创新中心 广谱性中和流感病毒的全人抗体
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
EP3946613A1 (en) * 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2020221450A1 (en) 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection
JP7634231B2 (ja) 2019-05-31 2025-02-21 ワシントン ユニバーシティ Pan-ノイラミニダーゼ阻害抗体
US20220298230A1 (en) 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
US11053724B2 (en) 2019-07-23 2021-07-06 Tony AWAD Device to assist in closing doors
US11448049B2 (en) 2019-09-05 2022-09-20 Flowco Production Solutions, LLC Gas assisted plunger lift control system and method
JP7611908B2 (ja) 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
US20250263466A1 (en) 2020-02-03 2025-08-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
EP4100054A4 (en) * 2020-02-07 2024-07-17 Washington University PROTECTIVE ANTIBODIES AGAINST INFLUENZA B
KR20220140568A (ko) 2020-02-11 2022-10-18 벤더르빌트 유니버시티 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
CN115210248A (zh) 2020-02-18 2022-10-18 北卡罗来纳大学查佩尔希尔分校 Aav衣壳-启动子相互作用和细胞选择性基因表达
PH12022552164A1 (en) 2020-02-19 2023-11-29 United Biomedical Inc Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
CN111704665B (zh) 2020-02-20 2022-04-01 南京农业大学 一种针对H3N2犬流感病毒的重组犬源化抗体scFv-Fc
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
JP2023517234A (ja) 2020-03-09 2023-04-24 アブセレラ バイオロジクス インコーポレイテッド 抗コロナウイルス抗体および使用の方法
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
CN111303280B (zh) 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
EP4127174A4 (en) 2020-03-23 2024-05-01 Monash University ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES
WO2021195326A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
WO2022075667A1 (ko) 2020-10-05 2022-04-14 한양대학교 산학협력단 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
WO2022082217A1 (en) 2020-10-16 2022-04-21 Eureka Therapeutics, Inc. Compositions for preventing or treating viral and other microbial infections

Similar Documents

Publication Publication Date Title
JP2009537143A5 (cg-RX-API-DMAC7.html)
JP2023082054A5 (cg-RX-API-DMAC7.html)
JP2018171063A5 (cg-RX-API-DMAC7.html)
JP2019524645A5 (cg-RX-API-DMAC7.html)
JP2018033454A5 (cg-RX-API-DMAC7.html)
JP2020519643A5 (cg-RX-API-DMAC7.html)
JP2009524429A5 (cg-RX-API-DMAC7.html)
JP2016508503A5 (cg-RX-API-DMAC7.html)
JP2011516423A5 (cg-RX-API-DMAC7.html)
JP2015212284A5 (cg-RX-API-DMAC7.html)
JP2008536483A5 (cg-RX-API-DMAC7.html)
JP2019506839A5 (cg-RX-API-DMAC7.html)
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
JP2020501532A5 (cg-RX-API-DMAC7.html)
JP2017514522A5 (cg-RX-API-DMAC7.html)
JP2009240315A5 (cg-RX-API-DMAC7.html)
JP2013517783A5 (cg-RX-API-DMAC7.html)
JP2012505902A5 (cg-RX-API-DMAC7.html)
JP2005120106A5 (cg-RX-API-DMAC7.html)
JP2019214579A5 (cg-RX-API-DMAC7.html)
JP2012531219A5 (cg-RX-API-DMAC7.html)
JP2017537084A5 (cg-RX-API-DMAC7.html)
JP2012519724A5 (cg-RX-API-DMAC7.html)
JP2023537070A5 (cg-RX-API-DMAC7.html)
JP2025512512A5 (cg-RX-API-DMAC7.html)